Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
Suite 110
San Diego,
CA 92121
Telefone: 858-552-2200
Fax: 858-552-2212
Web Site: http://www.amylin.com
| Amylin Pharmaceuticals, Inc., a biopharmaceutical company, focuses on improving the lives of people with diabetes, obesity, and other diseases through the discovery, development, and commercialization of innovative medicines. The company has developed and gained approval for two medicines for diabetes, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. The company also has research and development (R&D) programs in the therapeutic areas of diabetes and obesity. Its R&D programs for diabetes include exenatide once weekly, exenatide once weekly pen, exenatide suspension formulation, exenatide nasal, and the exenatide transdermal patch. The companys R&D programs for obesity comprise pramlintide/metreleptin combination therapy and davalintide. Amylin Pharmaceuticals markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It partners with Eli Lilly and Company for the development of exenatide; Alkermes, Inc. for the development of potential long-acting formulations of exenatide; and Biocon Limited to develop, commercialize, and manufacture a novel peptide therapeutic for the treatment of diabetes. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. |
|
| Principais estatísticas | Mais da Reuters
Descrição expandida da empresa |
| |
| | Pago | Exercido | Mr. Dan Bradbury , 48
Chief Exec. Officer, Pres, Director and Member of Fin. Committee |
$
655.00K |
$
0 | Mr. Mark G. Foletta C.P.A., 49
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
$
409.00K |
$
0 | Dr. Orville G. Kolterman M.D., 62
Sr. VP R&D |
$
432.00K |
$
495.00K | Ms. Marcea Bland Lloyd , 61
Sr. VP of Legal & Corp. Affairs and Gen. Counsel |
$
470.00K |
$
0 | Mr. Roger Marchetti , 51
Sr. VP of HR & Information Management |
$
356.00K |
$
0 |
|
|
|
Somas desde
31-Dec-08
e valores de compensação são para o ano fiscal que termina nesta data. "Pago" é salário, bônus, etc. "Exercício" é o valor de ações exercidas durante o ano fiscal.
| |
|
Ajuda
0.10 (0.58%) 
Perfil
A Reuters oferece mais 
